2023
Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms
Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.Peer-Reviewed Original ResearchConceptsPapillary mucinous neoplasmMalignant risk stratificationCACNA1G geneRisk stratificationMucinous neoplasmsBiomarker panelBackgroundIntraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmEarly detectionPrevious case-control studyHigh-grade dysplasiaCase-control studyPancreatic cancer precursorsReceiver Operating Characteristic (ROC) curve analysisSignificant diagnostic challengeCross-sectional imagingCharacteristic curve analysisOperating Characteristic curve analysisG geneHigh diagnostic specificityPrior validation studiesSignificant procedural riskIPMN tissuesSurgical resectionAdvanced neoplasia
2022
Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
Chhoda A, Sharma A, Tang H, Tan W, Sailo B, Peters N, Ying L, Ruzgar N, Kunstman J, Salem R, Farrell J, Ahuja N. Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. Gastroenterology 2022, 162: s-708. DOI: 10.1016/s0016-5085(22)61664-0.Peer-Reviewed Original ResearchTu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS
Singh S, Chhoda A, Vodusek Z, Khatri R, Gunderson C, McCarty T, Sharma P, Grimshaw A, Kunstman J, Sharma A, Ahuja N, Gonda T, Farrell J. Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2022, 162: s-907. DOI: 10.1016/s0016-5085(22)62148-6.Peer-Reviewed Original Research1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE
Khatri R, Chhoda A, Sharma A, Farrell J, Ahuja N, Ehrlich A, Friedenberg F. 1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE. Gastroenterology 2022, 162: s-270-s-271. DOI: 10.1016/s0016-5085(22)60641-3.Peer-Reviewed Original Research
2021
Sa298 IS IT SAFE TO STOP SURVEILLANCE OF PANCREATIC CYSTS AFTER 5 YEARS OF STABILITY?: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT EVIDENCE.
Chhoda A, Singh S, Sheth A, Sharma P, Sharma A, Kunstman J, Grimshaw A, Ahuja N, Farrell J. Sa298 IS IT SAFE TO STOP SURVEILLANCE OF PANCREATIC CYSTS AFTER 5 YEARS OF STABILITY?: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT EVIDENCE. Gastroenterology 2021, 160: s-475. DOI: 10.1016/s0016-5085(21)01841-2.Peer-Reviewed Original ResearchSa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS
Chhoda A, Singh S, Grimshaw A, Sheth A, Sharma A, Kunstman J, Ahuja N, Farrell J. Sa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2021, 160: s-477. DOI: 10.1016/s0016-5085(21)01845-x.Peer-Reviewed Original Research